Sayadi Leila, Varaei Shokoh, Babazadeh Zanjani Melika
Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
Int J Hematol Oncol Stem Cell Res. 2021 Jan 1;15(1):35-50. doi: 10.18502/ijhoscr.v15i1.5248.
Acute lymphoblastic leukemia is a disease of the hematopoietic system and chemotherapy is recommended as the primary treatment. As many chemotherapeutic agents have severe adverse effects, patients require to be supported by their family to deal with chemotherapy-related symptoms. This study attempted to investigate the effect of family-centered supportive programs on chemotherapy symptom control in patients with acute lymphoblastic leukemia. Sixty-six patients with acute lymphoblastic leukemia undergoing chemotherapy along with their caregivers participated in this nonrandomized clinical trial. Patients in Shariati and Taleghani Hospital were assigned to intervention (n=33) and control group (n=33), respectively. A survey of family-centered supportive program was conducted via in-person and telephone up to 6 cycles of chemotherapy. The chemotherapy symptom assessment scale was administered to record the data during 6 cycles of chemotherapy treatment. The control group only received routine interventions. Data were analyzed using Chi-square and Mann-Whitney U tests. The results of the study indicated that there was a statistically significant difference in terms of the frequency of 9 chemotherapy-induced symptoms including nausea, shortness of breath, problems related to skin and nails, a sore/sensitive mouth or throat, anorexia, weight gain or loss, headache and sore/scratchy/dry eyes between the control and intervention group. There was also a statistically significant difference in the severity and level of discomfort of 19 chemotherapy-induced symptoms between the control and intervention group. : Family-centered supportive program can be considered as an approach to decrease the frequency, severity and discomfort level of chemotherapy-induced symptoms.
急性淋巴细胞白血病是一种造血系统疾病，化疗被推荐作为主要治疗方法。由于许多化疗药物有严重的不良反应，患者需要家人的支持来应对化疗相关症状。本研究试图探讨以家庭为中心的支持项目对急性淋巴细胞白血病患者化疗症状控制的影响。66例接受化疗的急性淋巴细胞白血病患者及其照顾者参与了这项非随机临床试验。设拉子医院和塔勒哈尼医院的患者分别被分配到干预组（n = 33）和对照组（n = 33）。通过面对面和电话方式对以家庭为中心的支持项目进行调查，随访至化疗6个周期。在化疗的6个周期中使用化疗症状评估量表记录数据。对照组仅接受常规干预。采用卡方检验和曼-惠特尼U检验分析数据。研究结果表明，干预组和对照组在包括恶心、呼吸急促、皮肤和指甲问题、口腔或咽喉疼痛/敏感、厌食、体重增加或减轻、头痛以及眼睛疼痛/瘙痒/干涩在内的9种化疗引起的症状的发生频率方面存在统计学显著差异。干预组和对照组在19种化疗引起的症状的严重程度和不适水平方面也存在统计学显著差异。以家庭为中心的支持项目可被视为一种降低化疗引起症状的发生频率、严重程度和不适水平的方法。
